Oncgnostics GmbH developed the GynTect® test in order to prevent patients from this stressful period of uncertainty surrounding abnormal cervical cancer screening and follow-up results, and to offer doctors a quick and reliable cervical cancer diagnosis. This non-invasive test, performed from just one cervical smear, examines the DNA of cells for changes that indicate cervical cancer and its preliminary stages.
The innovation of the GynTect® test is the reliable detection of DNA methylation originally found in cervical carcinoma tissue, i.e. the alteration of the genetic material of abnormal cells. Thus, a cervical cancer diagnosis can be confirmed with certainty in a very short time or, in the case of supposedly positive Pap tests, the all-clear can be given. In previous studies, GynTect® reliably detected all cervical carcinomas, reason why the GynTect® test should be used in cervical cancer screening.